Reviva Pharmaceuticals Holdings (RVPH) Enterprise Value (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Enterprise Value of -$22.2 million for Q1 2026, down 53.68% sequentially from -$14.4 million in Q4 2025, and down 319.52% YoY from $10.1 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Enterprise Value (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Enterprise Value for 9 years, with the latest figure at -$22.2 million in Q1 2026.
- Quarterly Enterprise Value fell 319.52% year-over-year to -$22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.2 million (down 319.52% YoY) and the FY2025 annual result came in at -$14.4 million, down 7.14% from the prior year.
- Enterprise Value slipped to -$22.2 million in Q1 2026 per RVPH's latest filing, from -$14.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$5.0 million in Q3 2023 and troughed at -$23.4 million in Q1 2022.
- A 5-year average of -$14.0 million and a median of -$13.2 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2026: Enterprise Value surged 78.56% in 2023, then tumbled 319.52% in 2026.
- Over 5 years, Enterprise Value stood at -$18.5 million in 2022, then slipped by 26.18% to -$23.4 million in 2023, then surged by 42.33% to -$13.5 million in 2024, then retreated by 7.14% to -$14.4 million in 2025, then plunged by 53.68% to -$22.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$22.2 million, -$14.4 million, and -$13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -19.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.89 Mn |
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -14.44 Mn |
| Sep 30, 2025 | -13.18 Mn |
| Jun 30, 2025 | -10.36 Mn |
| Mar 31, 2025 | -5.29 Mn |
| Dec 31, 2024 | -13.48 Mn |
| Sep 30, 2024 | -5.56 Mn |
| Jun 30, 2024 | -6.18 Mn |
| Mar 31, 2024 | -11.97 Mn |
| Dec 31, 2023 | -23.37 Mn |
| Sep 30, 2023 | -4.97 Mn |
| Jun 30, 2023 | -11.15 Mn |
| Mar 31, 2023 | -11.26 Mn |
| Dec 31, 2022 | -18.52 Mn |
| Sep 30, 2022 | -23.19 Mn |
| Jun 30, 2022 | -19.42 Mn |
| Mar 31, 2022 | -23.42 Mn |
| Sep 30, 2021 | -33.49 Mn |
| Jun 30, 2021 | -35.80 Mn |